S. Blaj and P. Piso, “Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?”, Curr. Issues Pharm. Med. Sci., vol. 30, no. 4, pp. 207–210, Jan. 2018, doi: 10.1515/cipms-2017-0040.